{"id":9946,"date":"2024-01-12T12:32:27","date_gmt":"2024-01-12T11:32:27","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=9946"},"modified":"2024-03-27T12:44:44","modified_gmt":"2024-03-27T11:44:44","slug":"selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/","title":{"rendered":"Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital"},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">Cristina Su\u00e1rez Ferrer 1, Eduardo Martin-Arranz 2, Mar\u00eda Dolores Mart\u00edn-Arranz, Gastroenterol Hepatol 2024 Jan 12:S0210-5705(24)00018-9. doi: 10.1016\/j.gastrohep.2024.01.002. Online ahead of print.<br \/>\nAim:\u00a0Granulocyte and monocyte apheresis (GMA) is a potential therapeutic option when combined with various drugs for treatment of ulcerative colitis (UC). In this study, we analyze the efficacy and safety of GMA combined with vedolizumab (VDZ) during induction in patients with moderate-severe UC and incomplete response to steroids.<\/p>\n<p>Patients and methods:\u00a0Single-center retrospective review of patients receiving GMA+VDZ. Data on the disease and previous treatments were collected. Clinical response was classified as no response, response without remission, and remission. Available data on biochemical and endoscopic response were included. Adverse events (AEs) were recorded.<\/p>\n<p>Results:\u00a0The study population comprised 6 patients with UC who had received GMA+VDZ during induction after failure of an anti-TNF agent. The median number of GMA sessions was 5 (IQR 4-5; 3-10). All the patients received VDZ 300mg iv at 0, 2, and 6 weeks, and 5 (83%) received an additional dose at week 10. During maintenance, all the patients continued VDZ iv every 8 weeks. The median follow-up was 57.6 months (IQR: 39-74). Four of the 6 patients achieved clinical remission after GMA+VDZ and continued in deep remission until the end of follow-up. A median, non-significant decrease of 1378\u03bcg\/g (IQR: 924-5778\u03bcg\/g) was observed for calprotectin and 42.2mg\/l (IQR: 15.3-113.5) for CRP vs. baseline. No patient underwent colectomy. No treatment-related AEs were observed.<\/p>\n<p>Conclusions:\u00a0GMA+VDZ during induction can be effective and safe in selected patients with moderate-severe UC and partial response to steroids.\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Cristina Su\u00e1rez Ferrer 1, Eduardo Martin-Arranz 2, Mar\u00eda Dolores Mart\u00edn-Arranz, Gastroenterol Hepatol 2024 Jan 12:S0210-5705(24)00018-9. doi: 10.1016\/j.gastrohep.2024.01.002. Online ahead of print. Aim:\u00a0Granulocyte and monocyte apheresis (GMA) is a potential therapeutic option when combined with various drugs for treatment of ulcerative colitis (UC). In this study, we analyze the efficacy and safety of GMA combined with [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[303,595,343,424,451,627,505,156,136,527,306,66],"class_list":["post-9946","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-combination","scientific_tags-complete-clinical-remission","scientific_tags-faecal-calprotectin","scientific_tags-gma","scientific_tags-induction","scientific_tags-moderate-to-severe","scientific_tags-partial-response","scientific_tags-safety","scientific_tags-single-center","scientific_tags-steroid","scientific_tags-ulcerative-colitis","scientific_tags-vedolizumab"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Cristina Su\u00e1rez Ferrer 1, Eduardo Martin-Arranz 2, Mar\u00eda Dolores Mart\u00edn-Arranz, Gastroenterol Hepatol 2024 Jan 12:S0210-5705(24)00018-9. doi: 10.1016\/j.gastrohep.2024.01.002. Online ahead of print. Aim:\u00a0Granulocyte and monocyte apheresis (GMA) is a potential therapeutic option when combined with various drugs for treatment of ulcerative colitis (UC). In this study, we analyze the efficacy and safety of GMA combined with [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-27T11:44:44+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/\",\"name\":\"Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2024-01-12T11:32:27+00:00\",\"dateModified\":\"2024-03-27T11:44:44+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/","og_locale":"de_DE","og_type":"article","og_title":"Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital - Adacyte","og_description":"Cristina Su\u00e1rez Ferrer 1, Eduardo Martin-Arranz 2, Mar\u00eda Dolores Mart\u00edn-Arranz, Gastroenterol Hepatol 2024 Jan 12:S0210-5705(24)00018-9. doi: 10.1016\/j.gastrohep.2024.01.002. Online ahead of print. Aim:\u00a0Granulocyte and monocyte apheresis (GMA) is a potential therapeutic option when combined with various drugs for treatment of ulcerative colitis (UC). In this study, we analyze the efficacy and safety of GMA combined with [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/","og_site_name":"Adacyte","article_modified_time":"2024-03-27T11:44:44+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/","name":"Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2024-01-12T11:32:27+00:00","dateModified":"2024-03-27T11:44:44+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/selective-granulocyte-monocyte-apheresis-during-induction-with-vedolizumab-in-moderate-severe-ulcerative-colitis-experience-in-a-tertiary-hospital\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/9946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=9946"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=9946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}